Biosimilars can help reduce the high cost of oncology medicines spending1,2
Oncology innovation is booming, but costly for the healthcare system2

*Costs through 2026 are based on data reported by the IQVIA Oncology Link from April 2022. Costs beyond 2022 are projected growth based on a CAGR of 10.6% in the next 5 years.2

Learn about ZIEXTENZO (pegfilgrastim-bmez), the long-acting G-CSF treatment option from Sandoz4
CAGR=compound annual growth rate; G-CSF=granulocyte colony-stimulating factor.
References:
1. IQVIA Institute for Human Data Science. Global oncology trends 2018: innovation, expansion and disruption. https://www.iqvia.com/institute/reports/global-oncology-trends-2018. Accessed November 28, 2021. 2. IQVIA Institute for Human Data Science. Global oncology trends 2022: outlook to 2026. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2022. Accessed November 21, 2022. 3. IQVIA Institute for Human Data Science. Global oncology trends 2019: therapeutics, clinical development and health system implications. https://www.iqvia.com/institute/reports/global-oncology-trends-2019. Accessed November 21, 2022. 4. Socal M, Ballreich J, Chyr L, Anderson G. Biosimilar medications – savings opportunities for large employers. A report for ERIC – the ERISA Industry Committee. Department of Health Policy and Management. John Hopkins Bloomberg School of Public Health. March 2020. 5. Trautman H, Szabo E, James E, et al. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective. J Manag Care Spec Pharm. 2019;25:94-101. 6. Puckrein G, et al. Sandoz biosimilar Zarxio (filgrastim-sndz) reduced out-of-pocket costs for Medicare patients with breast cancer versus the reference medicine. Poster presented at: San Antonio Breast Cancer Symposium (SABCS); December 7, 2018; San Antonio, TX. 7. McBride A, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13:2285-2295. 8. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.